Condition: NMO Spectrum Disorder · Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd
The objectives of this phase Ib study are to evaluate the efficacy, safety, pharmacokinetics, pharmacodynamics and immunogenic profiles of B001 in subjects with aquaporin-4 antibody (AQP4-IgG) positive NMOSD.
This description comes directly from the study's public registry record.
Fu-Dong Shi, MD,PhD · 022-60814587 · Shifudong219@163.com
Always discuss trial participation with your own doctor first.
| Beijing Tiantan Hospital Capital Medical University | Beijing, Beijing Municipality, China | Recruiting |
| First Hospital of Shanxi Medical University | Taiyuan, Shanxi, China | Recruiting |
| Tangdu hospital,fourth military medical university | Xi’an, Shanxi, China | Recruiting |
| Tianjin Medical University General Hospital | Tianjin, Tianjin Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05145361